Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-CRT vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label),Facilitation of weaning from mechanical ventilation in neonates (off-label)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to nonlinear pharmacokinetics. Less than 15% excreted unchanged in urine.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
~40% bound to albumin (primarily); binding is concentration-independent.
65% bound to albumin
0.4-0.6 L/kg (slightly higher in infants); approximates total body water; distributes widely into tissues including breast milk and CNS.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 80-100%; Oral sustained-release: 90-100% (with less fluctuation); Rectal: 75-90% (variable due to absorption).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 25% and monitor levels. For GFR <10 m L/min: reduce dose by 50% and monitor closely.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor levels. Child-Pugh Class C: reduce dose by 75% or consider alternative; monitor levels closely.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Children >1 year: initial dose 10-16 mg/kg/day orally q12h (extended-release). Titrate to serum theophylline levels of 5-15 mcg/m L. Maximum 400 mg/day or 16 mg/kg/day, whichever is less.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients: start at lowest possible dose (e.g., 200-300 mg once daily) due to reduced clearance. Monitor serum theophylline levels closely; target lower end of therapeutic range (5-12 mcg/m L). Avoid use if possible due to increased risk of toxicity.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
Theophylline has a narrow therapeutic index; toxicity can occur at doses only slightly above therapeutic levels. Serious and potentially fatal adverse events, including seizures and cardiac arrhythmias, can occur, especially in patients with preexisting conditions or those receiving concurrent medications that affect theophylline clearance.
No FDA black box warning.
Monitor serum theophylline concentrations closely due to narrow therapeutic index (10-20 mcg/m L).,Use with caution in patients with cardiac disorders (e.g., arrhythmias), hepatic impairment, renal dysfunction, seizure disorders, and in elderly patients.,May exacerbate gastric ulcers and gastroesophageal reflux.,Drug interactions: CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones, macrolides) increase levels; CYP1A2 inducers (e.g., smoking, rifampin, phenytoin) decrease levels.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component of the formulation,Pre-existing seizure disorders (relative),Active peptic ulcer disease (relative),Uncontrolled cardiac arrhythmias (relative)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid charcoal-broiled foods as they may decrease theophylline levels. High-fat meals can alter absorption; take consistently with regard to meals. Caffeine-containing foods and beverages should be limited due to additive stimulation.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses but no major malformations. Second and third trimesters: No established teratogenicity; may cause neonatal toxicity (irritability, jitteriness, vomiting) if maternal levels are high near term. Use only if benefit outweighs risk.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Breastfeeding is generally considered compatible but may cause irritability or sleep disturbances in the infant. Monitor infant for signs of theophylline toxicity. Use lowest effective maternal dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
During pregnancy, theophylline clearance may increase (especially in second and third trimesters), requiring dose adjustments. Monitor serum concentrations closely and increase dose as needed to maintain therapeutic levels. Clearance returns to non-pregnant levels postpartum.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
SOMOPHYLLIN-CRT (theophylline) is a controlled-release formulation for chronic asthma/COPD. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active seizures. Use with caution in hepatic impairment, heart failure, and elderly. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and phenytoin decrease levels.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Swallow tablets whole; do not crush or chew.,Take at the same time each day with a full glass of water.,Avoid excessive caffeine (coffee, tea, cola, chocolate) to prevent increased stimulation.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Do not change brand or formulation without consulting your doctor.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-CRT vs AEROLATE, answered by our medical review team.
SOMOPHYLLIN-CRT is a Bronchodilator that works by Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-CRT and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-CRT is: Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-CRT and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-CRT is classified as Category C. Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.